中文BIGBEAR Pharmaceutical announces the approval of Pralsetinib in Laos
Vientiane, Laos - August 12 2024 - BigBear Pharma, a leading biopharmaceutical c
BIGBEAR Pharmaceutical announces the approval of TAZEMETOSTAT in Laos
Vientiane, Laos - August 01 2024 - BigBear Pharma, a leading biopharmaceutical c
BIGBEAR Pharmaceutical announces the approval of Adagrasib in Laos
Vientiane, Laos - July 14, 2024 - BigBear Pharma, a leading biopharmaceutical co
BIGBEAR Pharmaceutical announces the approval of Larotrectinib in Laos
Vientiane, Laos - May 30, 2024 - BigBear Pharma, a leading biopharmaceutical com
BIGBEAR Pharmaceutical announces the approval of baricitinib and selumetinib in Laos
Vientiane, Laos - April 8, 2024 - BigBear Pharma, a leading biopharmaceutical co
Big Bear Pharmaceutical Announces Trelagliptin and Ivosidenib Approved in Laos
Laos Vientiane-January 03, 2024-BigBear Pharma, a leading alchemon company focus
Big Bear Pharmaceutical Announces Selpercatinib Entrectinib and Enasidenib Approved in Laos
Laos Vientiane-October 11, 2023-BigBear Pharma, a leading alchemon company focus
Big Bear Pharmaceutical Announces Pomalidomide and Pemigatinib Approved in Laos
Laos Vientiane-October 10, 2023-BigBear Pharma, a leading alchemon company focusing on development and commercial cancer innovation therapy, announced today that two products have been approved by the
BigBear Pharmaceutical announced that Eltrombopag was approved in Laos
Vientiane, Laos - September 22, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that Cabozantini
Big Bear Pharmaceutical Announces Isazomib, Lenalidomide, Mitotane, Tofacitinib, Tucatinib, Deucravacitinib and Upadatin
Vientiane, Laos - August 22, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that seven products